Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2907737 | 0.92 | LMNA (0.33) | PIK3R1PIK3CAMAPTKDM4DLMNA | |
| SCHEMBL2908342 | 0.86 | ITGB2 (0.38) | MAPTKDM4DMCL1 | |
| SCHEMBL2901677 | 0.85 | MAPT (0.39) | MAPTMCL1 | |
| SCHEMBL2903067 | 0.85 | OPRD1 (0.37) | PIK3R1PIK3CA | |
| SCHEMBL2902613 | 0.85 | PIK3R1 (0.37) | LRRK2PIK3R1PIK3CAMAPTLMNA | |
| SCHEMBL2907788 | 0.85 | LMNA (0.37) | MAPTLMNA | |
| SCHEMBL2910374 | 0.83 | ALDH1A1 (0.41) | PIK3R1PIK3CAMAPTLMNAMCL1 | |
| Morpholine SCHEMBL2905731 | 0.82 | OPRD1 (0.35) | LRRK2PIK3R1PIK3CAMAPTLMNA | |
| SCHEMBL2902357 | 0.81 | HRH3 (0.37) | PIK3R1PIK3CAMAPTLMNA | |
| SCHEMBL2904791 | 0.79 | CYP3A4 (0.42) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1611107-B1 | 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS | MERCK PATENT GMBH (DE) | 2010-08-18 | — | — | EP | claimed |
| EP-1611107-B1 | 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS | MERCK PATENT GMBH (DE) | 2010-08-18 | — | — | EP | disclosed |
| US-7566709-B2 | 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders | MERCK PATENT GMBH (DE) | 2009-07-28 | — | — | US | disclosed |
| US-20070105871-A1 | 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders | MERCK PATENT GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105871-A1 | 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders | HTR1A, HTR1D, HTR5A | LRRK2 994/4885PIK3R1 2479/4885PIK3CA 3500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.